Challenges and advances in drug resistance and tolerance in cancer

Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.

Nature cancer·2026

17β-Estradiol Modulates Cancer Cell-Fibroblast Communication via Autophagy-Mediated Extracellular Vesicle Secretion and Promotes Poor Prognosis in Non-Small Cell Lung Cancer.

International journal of molecular sciences·2026

Prostate cancer: evading immunity, inspiring therapy.

Trends in cancer·2026

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Investigational new drugs·2026

Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability.

Nature cell biology·2026

Methodological advances to analyze cancer-associated fibroblast-derived ECM effects on macrophage polarization.

Methods in cell biology·2026

Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma.

Journal of experimental & clinical cancer research : CR·2026

Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.

Journal of experimental & clinical cancer research : CR·2026

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Journal of experimental & clinical cancer research : CR·2026

Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model.

Journal of experimental & clinical cancer research : CR·2026

Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma.

Journal of experimental & clinical cancer research : CR·2026

TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors.

Journal of experimental & clinical cancer research : CR·2026

ANAPC7 promotes triple-negative breast cancer progression through ANAPC2-dependent degradation of PCGF2 and activation of STAT3.

Molecular cancer research : MCR·2026

pH-Responsive drug delivery system for tumor therapy.

Nanoscale·2026

Spatiotemporally controlled degradation of CDK6 via light-triggered ROS generation: uncovering the proximity effect-mediated dual target depletion.

Organic & biomolecular chemistry·2026

Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models.

Cancer immunology research·2026

Targeting RAS for Pancreatic Cancer Interception.

Cancer discovery·2026

Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.

Cancer science·2026

Related Experiment Videos

Challenges and advances in drug resistance and tolerance in cancer

Related Concept Videos

Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.

17β-Estradiol Modulates Cancer Cell-Fibroblast Communication via Autophagy-Mediated Extracellular Vesicle Secretion and Promotes Poor Prognosis in Non-Small Cell Lung Cancer.

Prostate cancer: evading immunity, inspiring therapy.

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability.

Methodological advances to analyze cancer-associated fibroblast-derived ECM effects on macrophage polarization.

Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma.

Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model.

Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma.

TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors.

ANAPC7 promotes triple-negative breast cancer progression through ANAPC2-dependent degradation of PCGF2 and activation of STAT3.

pH-Responsive drug delivery system for tumor therapy.

Spatiotemporally controlled degradation of CDK6 via light-triggered ROS generation: uncovering the proximity effect-mediated dual target depletion.

Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models.

Targeting RAS for Pancreatic Cancer Interception.

Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.

Related Experiment Videos

Challenges and advances in drug resistance and tolerance in cancer

Related Concept Videos

Related Articles